Remus Pharmaceuticals Limited, incorporated in 2015, is a pharmaceutical company focused on developing and improving healthcare through innovative solutions, cutting-edge research, and essential medicines. The company was originally incorporated as 'Remus Pharmaceuticals Private Limited' on September 21, 2015, and subsequently converted from a private to public company, with its name changed to "Remus Pharmaceuticals Limited" on January 06, 2023.
Remus Pharmaceuticals Limited is an India-based company engaged in marketing and distribution of finished formulations of pharmaceutical drugs, and also deals in active pharmaceutical ingredients (APIs). The company provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
Remus and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms. The company's product portfolio comprises therapeutic drugs including ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Anti-inflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocular-hypertension, Urology and Vitamin deficiency.
The company deals in various drug forms including Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, and Sachet. As of January 31, 2023, the product portfolio consisted of 429 products, with 295 products registered in a total of 13 countries.
The pharmaceutical business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant. The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence.
As of January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and contract manufacturing supply, with clients spread across more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.
The company's products are marketed on a comprehensive scale to meet global demand, working closely with distributors to provide high-quality medicines that are available in every pharmacy. The research team analyses market trends, and targets recently getting off patented products for swift movement in the market.
Remus Pharmaceuticals completed its Initial Public Offering (IPO) in May 2023, with bidding from May 17-19, 2023, and shares listed on NSE SME on May 29, 2023. The IPO was priced at ₹1,229 per share with a minimum investment of ₹1,15,000 for retail investors.
The company incorporated 'Relius Pharmaceuticals SRL' as a new subsidiary company in Bolivia, effective on October 13, 2023. The company acquired a majority stake (56.67%) of a USA-based company, namely Espee Global Holdings LLC, making it a subsidiary effective on January 1, 2024.
On June 23, 2025, bonus shares were approved via postal ballot with 30.72 lakh votes in favor.
As per the latest available data, Remus Pharmaceuticals reported revenue of ₹620 crores and profit of ₹38.4 crores. The company is almost debt-free. Debtor days have improved significantly from 130 to 63.6 days.
• Revenue: ₹620 crores
• Profit: ₹38.4 crores
• Promoter Holding: 70.8%
• EPS: ₹65.21 for FY 2024-25
• Market Capitalization: ₹1,124 crores (down -14.1% in 1 year)
• 52-Week High: ₹1,417.38
• 52-Week Low: ₹890.53
• Price-to-Earnings (PE) Ratio: 56.50
The company conducts stage-by-stage safe, fair, and confidential clinical trials to determine the safety and effectiveness of new drugs, treatments, and diagnostic methods. With decades of experience fulfilling regulatory needs, the proficient team acts as the backbone of the organization, strongly emphasizing maintaining quality by following proper methodology and serving benchmark standards with higher approvals.
Remus Pharmaceuticals represents a growing pharmaceutical company with a strong focus on generic formulations, international expansion, and maintaining high-quality standards in drug manufacturing and distribution. The company's strategic positioning in critical therapeutic areas and expanding global footprint position it well for future growth in the pharmaceutical sector.
